Cost-benefit analysis of universal screening for HCV infection in China: a Markov modelling study
文献类型：期刊论文
| 作者 | Zhou, Dachuang1,7; Xu, Liangxiu7; Zhong, Yimei1,7; Xu, Zhehong6; Wang, Jun2; Wang, Yuntian3,4; Gao, Yiyang1,7; Xie, Jing5; Xia, Yuting1,7; Tang, Wenxi1,7 |
| 刊名 | BMC HEALTH SERVICES RESEARCH
 |
| 出版日期 | 2025-09-30 |
| 卷号 | 25期号:1页码:10 |
| 关键词 | Hepatitis C Health economics Cost-effectiveness China |
| DOI | 10.1186/s12913-025-13349-6 |
| 英文摘要 | BackgroundHepatitis C virus (HCV) infection remains a major public health concern in China, contributing substantially to global HCV-related morbidity and mortality. In line with the World Health Organization (WHO) targets for HCV elimination by 2030, this study aimed to evaluate the long-term health and economic outcomes of universal HCV screening strategies in China.MethodsA decision-analytic Markov model was developed to simulate HCV disease progression and healthcare costs over a 30-year time horizon (2026-2055). A total of 81 scenarios were assessed, including 80 universal screening strategies and a no-screening comparator. Strategies varied by age group (3-10, 20-60, 60-80, or 3-80 years), screening duration (10 or 30 years), and frequency (once in 2026, or repeated every 10, 5, 3, 2 years, or annually). Model inputs were derived from published literature and national data. Cost-effectiveness was evaluated using a willingness-to-pay (WTP) threshold based on China's 2023 per capita gross domestic product, with future costs and health outcomes discounted at 5% annually. Deterministic and probabilistic sensitivity analyses were conducted.ResultsUniversal HCV screening was both effective and cost-effective in the majority of scenarios, with 74 out of 80 strategies demonstrating favorable cost-effectiveness ratios. Eighteen strategies met the WHO target for HCV-related mortality reduction before 2040. The most cost-effective approach-screening individuals aged 3-80 years every 5 years for 10 years-yielded an incremental net monetary benefit of US$98.99 billion (95% CI: US$10.18-190.15 billion), while reducing healthcare expenditures by US$126.67 billion compared to no screening. The required investment for screening was US$3.24 billion. Findings were robust in sensitivity analyses.ConclusionsUniversal HCV screening every 5 years for individuals aged 3-80 years over a 10-year period is highly cost-effective in China and supports national efforts toward achieving WHO HCV elimination targets. These results provide evidence to inform policy decisions in China and other middle-income settings. |
| WOS关键词 | CHRONIC HEPATITIS-C ; ELIMINATION ; GUIDANCE ; HEALTH |
| 资助项目 | National Natural Science Foundation of China, International Cooperative Research Project |
| WOS研究方向 | Health Care Sciences & Services |
| 语种 | 英语 |
| WOS记录号 | WOS:001586141400002 |
| 出版者 | BMC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321612]  |
| 专题 | 国家级研究中心_原创新药研究全国重点实验室 |
| 通讯作者 | Tang, Wenxi |
| 作者单位 | 1.China Pharmaceut Univ, Sch Int Pharmaceut Business, Dept Publ Affairs Management, 639 Longmian Rd, Nanjing 211198, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Mol Imaging Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, Inst Automat, State Key Lab Multimodal Artificial Intelligence S, Beijing 100190, Peoples R China 4.Hainan Univ, Sch Informat & Commun Engn, Haikou 570228, Peoples R China 5.Southeast Univ, Zhongda Hosp, Sch Med, Dept Pharm, Nanjing 210009, Peoples R China 6.Xiamen Univ, Paula & Gregory Chow Inst Studies Econ, Xiamen 361005, Peoples R China 7.China Pharmaceut Univ, Ctr Pharmacoecon & Outcomes Res, Nanjing 211198, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhou, Dachuang,Xu, Liangxiu,Zhong, Yimei,et al. Cost-benefit analysis of universal screening for HCV infection in China: a Markov modelling study[J]. BMC HEALTH SERVICES RESEARCH,2025,25(1):10. |
| APA | Zhou, Dachuang.,Xu, Liangxiu.,Zhong, Yimei.,Xu, Zhehong.,Wang, Jun.,...&Tang, Wenxi.(2025).Cost-benefit analysis of universal screening for HCV infection in China: a Markov modelling study.BMC HEALTH SERVICES RESEARCH,25(1),10. |
| MLA | Zhou, Dachuang,et al."Cost-benefit analysis of universal screening for HCV infection in China: a Markov modelling study".BMC HEALTH SERVICES RESEARCH 25.1(2025):10. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。